To provide the FDA with a comprehensive understanding of Myhre syndrome, including the lived experiences of patients and caregivers, the community met with the FDA in December 2024. The full report is out now.
Read moreAnnouncing New Research Partnership with Emory University
We are excited to announce the launch of our new partnership with Emory University designed to shed light on the underlying molecular mechanisms of Myhre Syndrome and lay the foundation for future treatments.
Read moreGenetically Modified T Cell Study Confirms Safety
Genetically modified T cell therapies have been in the news for their ability to improve outcomes for cancer patients, and a recent longitudinal study confirmed that serious complications were extremely rare.
Read moreAdvancing Research and Hope: Exciting Development in Fibrosis Research
Encouraging Progress in Fibrosis Research
Rare Disease Day 2025 is the perfect day to see an announcement on the new advancements in understanding and treating fibrosis. A new initiative led by our Scientific Advisory Board member, Dr. Maria Macías, and her team at IRB Barcelona is focusing on developing potential therapies for fibrosis-related diseases like Myhre syndrome. Their work is centered on identifying innovative treatment strategies that target key molecular mechanisms involved in disease progression.
Dr. Macías’ research explores how specific proteins in the SMAD family influence fibrosis development. Her team is currently working on an initiative aimed at creating a new class of drugs designed to slow the progression of fibrosis. By refining drug design through structural analysis, they hope to develop a more precise and effective approach to managing Myhre syndrome.
While this research holds significant promise for Myhre syndrome, it also has wider implications for conditions such as idiopathic pulmonary fibrosis and cardiac fibrosis. Developing targeted treatments could lead to advancements that benefit a broad range of patients with fibrosis-related organ failure.
We remain committed to championing research that can lead to meaningful medical breakthroughs and are collaborating with Maria Macias and IRB Barcelona for our preclinical projects. We look forward to continued progress in developing therapies that can improve the outcomes for Myhre syndrome patients worldwide.
This initiative is supported through funding from the Agency for Management of University and Research Grants (AGAUR). We extend our appreciation to the dedicated researchers and supporters working toward innovative solutions for fibrosis-related diseases.
Read the full press release and see a video from IRB Barcelona here
Medical Advisory Board Doctors Recognized for their Research Contributions
Congratulations to Dr. Callewaert and Pr. Cormier-Daire, who have won pretigous awards for their rare disease research.
Read moreResearch Grant to Explore New Therapy for Myhre Syndrome
We are proud to announce a $450,000 grant to fund a groundbreaking research project designed by Genethon, collaborating with Professor Valérie Cormier-Daire (Genomic Medicine Service for Rare Diseases, Necker-Enfants Malades Hospital) in France.
Read moreMyhre Masterpieces Art Auction for Rare Disease Day
We’re thrilled to announce a special Rare Disease Day 2025 event—the Myhre Masterpieces Art Auction! We’re inviting members of the Myhre community to create one-of-a-kind artworks that will be featured in our art auction.
Read moreExciting News: Myhre Syndrome Clinic Opens at Stanford!
We’re thrilled to announce the opening of a dedicated Myhre Syndrome Clinic at Stanford University’s Cardiovascular Connective Tissue Clinic in California, USA. This clinic brings together experts in genetics, cardiology, and other specialties to provide personalized care for patients and families while advancing research into Myhre syndrome.
Read moreMSF Personal Essay in the American Journal of Medical Genetics
Last year, we were approached to submit an essay for the American Journal of Medical Genetics discussing the work we’re doing at the foundation. Kate Wears, our Executive Director, jumped at the chance to raise awareness and share the foundation’s mission with a wider audience.
Read moreiPSCs in Development for Myhre Syndrome
In June, we announced we'd be able to provide researchers with patient-derived iPS cell lines to accelerate our understanding of Myhre syndrome.
Read more